Table 1 Demographics for TCGA HNSCC patients analyzed in this study (progressors and nonprogressors)
From: IL-10 and integrin signaling pathways are associated with head and neck cancer progression
Patients (n = 235) | |
|---|---|
Age (mean) | 20–90 (62) |
Gender (M/F) | 173(74 %)/62(26 %) |
Race (W/B/A/AI/NA)a | 212(90 %)/12(4.5 %)/4(2 %)/2(1 %)/5(2.5 %) |
Smoke (Y/N/NA) | 181(77 %)/52(22 %)/2(1 %) |
Alcohol (Y/N/NA) | 169(71.5 %)/61(26 %)/5(2.5 %) |
HPV p16 or ISH (+/−/NA) | 19(8 %)/49(21 %)/167(71 %) |
Site (OC/OPX/L)b | 135(57 %)/41(18 %)/59(25 %) |
T Stage (T1-T2/T3/T4/TX/NA) | 80(34 %)/64(27 %)/87(37 %)/3(1.5 %)/1(0.5 %) |
N Stage (N0/N+/NA) | 107(45.5 %)/127(54 %)/1(0.5 %) |
Tumor Stage (I-III/IV/NA) | 96(41 %)/135(57 %)/4(2 %) |
Margin Status (+/−/Close/NA) | 17(7 %)/158(67 %)/22(10 %)/38(16 %) |
Nodal Extracapsular Spread (GE/ME/NE/NA)c | 13(6 %)/34(14 %)/114(49 %)/74(31 %) |
Curated Therapy: Therapy (C/R/CR/CRTM/CRTMV/NA)d | 5(2 %)/60(26 %)/95(40 %)/1(0.5 %)/1(0.5 %)/73(31 %) |
Radiation data: Radiation Dose cGy (mean) | 9–7380 (4720) |
Follow-up data: Follow-up Days (median) | 45–4241 (530.5) |
Follow-up data: Mortality (Living/Deceased) | 164(69.5 %)/71(30.5 %) |
Follow-up data: Days to Death (median) | 23–5152 (456) |
Follow-up data: Days to New Tumor (median) | 50–1859 (339) |
Radiation Treatment (Y/N) | 165(70 %)/70(30 %) |
Progression (Y/N) | 68(29 %)/167(71 %) |